Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pep2dia vs Metformin with Letrozole in PCOS
NCT06452511Phase 1Completed
- Start
- Aug 2024
- Primary completion
- Mar 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Pep2Dia in polycystic ovary syndrome (PCOS) (2 arms). Primary endpoint: Pregnancy rate at 6 months. Started Aug 2024; status: completed.
02
Drugs
Pep2Dia
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on NCT06452511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06452511.